We have all had the experience of ordering something online, watching the delivery truck icon crawl across the map for three days, and then opening the box to find everything is exactly fine. No harm, no foul, just a mildly stressful shipping odyssey. Now imagine a plaintiff’s lawyer showing up at your door insisting that because the box could have arrived damaged, you should treat it as if it did arrive damaged and sue somebody for the full purchase price. That is, more or less, the theory a relator tried to sell the court in Ellis v. CVS Health Corp., 2026 U.S. Dist. LEXIS 137176 (E.D. Pa. Jun. 22, 2026), a False Claims Act (“FCA”) case decided earlier this summer, and we are pleased to report the court was not buying what he was selling.
The case is a qui tam action concerning biologics, complex protein-based medications that need to be shipped within a specific temperature range because their chemical structure. Their medical value can degrade if they get too hot or too cold for too long. That much is undisputed. It is also undisputed that shipping biologics to patients’ homes, so-called “cold-chain” shipping, carries an inherent risk of what the industry calls “excursions,” meaning brief exposures outside the labeled storage temperature. Id. at *31.
By the time the case reached summary judgment, what remained was a single theory — that three specific temperature-sensitive drugs were “worthless services” under the FCA because of the shipping temperature issues, meaning the government had effectively paid for nothing when it reimbursed pharmacies for these medications. The missing ingredient was any actual proof that any drug was actually worthless.
Worthless services claims under the FCA require the plaintiff to show that what the government paid for had no medical value, not just diminished value — “[s]ervices that are ‘worth less’ are not ‘worthless.’” Id. at *23. After years of litigation and nearly six years of a government investigation that ultimately declined to intervene, plaintiff still could not identify a single dose of any of the drugs that was actually damaged by a shipping excursion. The manufacturers’ own stability studies, which measure how much temperature stress a given drug can withstand before losing potency, showed that the drugs could tolerate colder temperatures for longer than the excursions plaintiff alleged. A fact plaintiff conceded. Id. at *14.
So, plaintiff tried to build a workaround. Lacking proof that any given biologic was actually compromised, plaintiff argued that the shipping process was so “systemically vulnerable,” and defendant’s methods so “utterly deficient,” that the medications could simply be presumed compromised, or at least presumed unmarketable, without any need to show actual impairment. The court was having none of it. In the court’s words, this theory “would take the concept of worthless services to an untenable extreme, finding medical worthlessness with no evidence that any drug’s efficacy was impaired in any way.” Id. at *4.
That is about as clean a rejection as a defendant could hope for, and it is worth sitting with for a second. The court did not say plaintiff’s proof was thin. The court said the entire theory, taken on its own terms, would prove too much. Under plaintiff’s logic, any risk of temperature deviation, no matter how brief, no matter whether it ever actually affected the drug, would be enough to render an entire product line “worthless” and trigger fraud liability under a statute whose whole premise is proof of a false claim.
Plaintiff threw a fair amount of expert firepower at the problem, including a pharmacy practice expert, a packaging design engineer, and a chemist. The packaging and pharmacy experts offered opinions that defendant’s shipping practices were inadequate. But as the court noted, criticizing a company’s process is not the same as proving damage to the product, and “[f]laws in [defendant’s] procedures do not inexorably prove flaws in the drugs.” Id. at *17. The chemistry expert came closest to the mark, theorizing that different rates of freezing and thawing could cause different degrees of protein damage through a phenomenon called cryo-concentration. Interesting theory. Untested theory. On cross-examination, the expert admitted that confirming which effect actually occurred would require running an actual test replicating the shipping conditions, and he never ran one. He just “extracted” data from other people’s studies and reached his own conclusion. The court was unimpressed. Hypothesis is not a substitute for evidence, particularly when “substantial data . . . flatly contradicts an expert’s theory.” Id. at *19. An opinion that a bad process could theoretically cause harm is not the same as evidence that harm occurred, and a court is not required to let a jury fill that gap with speculation.
When the science did not cooperate, plaintiff pivoted to an economics-flavored argument that the drugs were “economically worthless” because they were technically eligible for return under defendant’s customer-friendly replacement policy, regardless of whether their potency was ever actually affected. Plaintiff’s expert economist testified that the drugs would be economically worthless “even if the stability, efficacy, and safety of the medicine were not affected” by the shipping process. Id. at *21. The court shut this down explaining that this theory rests on a “presumed market value,” which is “a construct not found in the False Claims Act, or any decision applying it.” Id. And logically, the court noted, “if the medication had therapeutic value, securing payment for it cannot constitute fraud.” Id. at *21-22. We appreciate a court that is willing to call a made-up legal concept exactly what it is. Whether a drug has therapeutic value is, as this court correctly framed it, a binary question. It either does or it does not. Maybe doesn’t get the job done.
Plaintiff’s argument that the court spent the most time on was that the FDA-approved label and the United States Pharmacopeia amounted to absolute standards, such that any excursion outside the ranges they identify was a per se violation supporting a finding of worthlessness. The court walked through how worthless services claims can, in appropriate cases, borrow standards from regulations or industry practice to define what counts as worthless, particularly where the product either works or does not work on a “black-and-white” scale, and where noncompliance is so extreme it amounts to gross negligence. But the court found that neither the FDA label nor the USP came close to establishing the strict, zero-tolerance rule plaintiff needed.
On the FDA label, the court noted that the label simply specifies one of a few general storage categories and “do[es] not purport to address the effects of excursions on the medications or . . . how the drugs should be transported.” Id. at *29. The USP fared no better for plaintiff. The court pointed to language explicitly acknowledging that drugs “may be held at temperatures outside their labeled storage requirements” and that excursions “may be acceptable provided stability data and scientific/technical justification exists demonstrating that product quality is not affected.” Id. at *33-34. In other words, the USP itself assumes excursions happen and builds in a process for evaluating them rather than banning them outright.
The court also found defendant’s conduct cut against any finding of gross negligence. Defendant spent time and money testing and re-testing the packaging and maintained a policy of promptly replacing any drug reported to have arrived frozen, which the court noted was one of the two compliance options the USP itself offers pharmacies when a deviation is reported. Id. at *34. An organization that is trying, even imperfectly, is not an organization acting “without even slight care.” Id. at *27.
We flag this decision not just for our FCA enthusiasts, but for anyone defending economic loss class actions built on a similar architecture — plaintiff cannot prove that any specific unit of a product actually failed, so plaintiff instead argues that the entire product line, or an entire class of transactions, should be treated as categorically worthless or defective because of a generalized, systemic risk that harm could have occurred somewhere, to someone, at some point. Strip away the FCA-specific vocabulary and this court’s reasoning offers a useful playbook for knocking down economic loss claims regardless of the statute involved.
The relator here had six years of government investigation and years of party discovery to find one damaged dose and could not do it. In the end all he could do was advance multiple theories asking the court to treat speculation as proof. Instead, the court granted summary judgment. The box arriving a little cold did not mean everything inside it was ruined. Some shipments really do arrive exactly fine. This one, for defendant, arrived on time and intact.
Recent Comments